Stocktoria
Nurix Therapeutics, Inc. NRIX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-07-24
Nurix Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $84.0M | $54.5M | $77.0M | $38.6M | $29.8M | $17.8M | $31.1M |
| R&D expense | $316.9M | $221.6M | $189.1M | $184.5M | $116.4M | $66.5M | $45.0M |
| Operating income | -$285.7M | -$213.0M | -$155.1M | -$183.9M | -$117.9M | -$65.0M | -$22.2M |
| Income tax | $760,000 | $270,000 | $0 | $0 | $131,000 | -$20.5M | $239,000 |
| Net income | -$264.5M | -$193.6M | -$143.9M | -$180.4M | -$117.2M | -$43.2M | -$21.7M |
| EPS (diluted) | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 | — | — |
| Operating cash flow | -$249.5M | -$172.6M | -$81.4M | -$159.8M | -$84.4M | -$80,000 | $601,000 |
| Free cash flow | -$263.5M | -$181.9M | -$89.8M | -$172.1M | -$90.0M | -$4.6M | -$1.1M |
| Cash & equivalents | $247.0M | $110.0M | $54.6M | $64.5M | $80.5M | $119.4M | $34.8M |
| Total assets | $688.1M | $669.3M | $355.6M | $416.8M | $476.8M | $396.3M | $44.0M |
| Total liabilities | $149.4M | $142.3M | $155.1M | $113.1M | $134.5M | $106.1M | $53.6M |
| Shareholders' equity | $538.7M | $527.0M | $200.5M | $303.7M | $342.3M | $290.3M | -$57.7M |
Growth · year-over-year · Revenue CAGR 18%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +54.0% | -29.1% | +99.3% | +29.8% | +66.9% | -42.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-11-30. Facts plus Stocktoria's own computed scores — not investment advice.